

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>El-Hibri Fuad</u> (Last) (First) (Middle) 2273 RESEARCH BLVD, SUITE 400 (Street) ROCKVILLE MD 20850 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Emergent BioSolutions Inc. [EBS]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) CEO & Chariman
	3. Date of Earliest Transaction (Month/Day/Year) 04/17/2008	
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/17/2008		j ⁽¹⁾⁽²⁾⁽³⁾		332,984	D	(1)(2)(3)	7,981,835 ⁽¹⁾⁽²⁾⁽³⁾	I	By Intervac, L.L.C
Common Stock								246,992 ⁽⁴⁾	D	
Common Stock								3,665,043 ⁽⁴⁾	I	By BioPharm, L.L.C.
Common Stock								1,559,155 ⁽⁵⁾	I	By Biovac, L.L.C.
Common Stock								719,275 ⁽⁶⁾	I	By Intervac Management, L.L.C.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

Explanation of Responses:

- On August 16, 2007, the father of Fuad El-Hibri gave him a gift of the capital stock of an entity that held equity interests in Intervac, L.L.C. such that Mr. El-Hibri acquired indirect beneficial ownership of a 4.0046% equity interest in Intervac, L.L.C., which increased the equity interest in Intervac, L.L.C. held by Mr. El-Hibri, together with the equity interest directly held by himself and his wife, as tenants by the entirety, to 36.5046% in aggregate.
- On April 17, 2008, Intervac, L.L.C. redeemed a 4.0047% equity interest of a member of Intervac, L.L.C. in exchange for a transfer of 332,984 shares of Common Stock of the issuer to such member. As a result, Intervac, L.L.C. is now the direct owner of 7,981,835 shares of Common Stock of the issuer.
- As a result of the redemption, the ownership interests in Intervac, L.L.C. of all members increased proportionately. Accordingly, the equity interest in Intervac, L.L.C. indirectly held by Mr. El-Hibri, together with the equity interest directly held with his wife, as tenants by the entirety, in Intervac, L.L.C., increased to 38.0276% in the aggregate. This increased ownership percentage in a smaller number of shares of Common Stock of the issuer had no effect on Mr. El-Hibri's pecuniary interest in shares of Common Stock of the issuer. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 3,035,300 shares.
- On April 16, 2008, BioPharm, L.L.C. made a pro rata distribution of 400,000 shares of Common Stock for no consideration that reduced Mr. El-Hibri's indirect ownership through BioPharm, L.L.C. by 400,000 shares. As a result of the pro rata distribution, Mr. El-Hibri received 160,680 shares of Common Stock from BioPharm, L.L.C. for no consideration that he now holds directly. Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 3,665,043 shares of Common Stock following the above-referenced in-kind pro rata distribution to its members for no consideration. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,472,248 shares.
- Mr. El-Hibri holds with his wife, as tenants by the entirety, a 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,599,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,426,446 shares.
- Mr. El-Hibri holds with his wife, as tenants by the entirety, a 31.11% equity interest in Intervac Management, L.L.C. Intervac Management, L.L.C. is the direct owner of 719,275 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 223,766 shares.

/s/Denise Esposito, attorney-in-fact 04/21/2008

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

